No Data
No Data
Sector Update: Health Care Stocks Higher Late Afternoon
Kyverna Gains as FDA Clears Trial for Lead Therapy
Kyverna Therapeutics Gets FDA IND Clearance for KYV-101
Express News | Kyverna Therapeutics Shares Are Trading Higher After the Company Announced KYV-101 Received FDA IND Clearance for the Treatment of Patients With Treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
Express News | Kyverna's Kyv-101 Receives U.S. FDA Ind Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the Kysa-8 Phase 2 Trial
Sector Update: Health Care Stocks Decrease Late Afternoon